the chairmans blog

Gary Rabin

 

Gary Rabin has a 25-year career in finance and operations that primarily encompasses investing in, managing and capital-raising for small-cap and emerging growth companies.
(read full bio)

Official Advanced Cell Technology, Inc social media
 

2013: The Year Regenerative Medicine Hits Its Stride

Posted by Gary Rabin on January 9, 2013 for Advanced Cell Technology, Inc
Greetings, As 2013 quickly ramps up, I thought I would take a few minutes to reflect on 2012 and share with you why I think 2013 is going to be an enormously important year both for ACT and for the regenerative [...]
Full Story »

Reflecting on Today’s Announcement: Our Best Financing Deal Ever

Posted by Gary Rabin on September 20, 2012 for Advanced Cell Technology, Inc
Greetings, I’d like to share a little extra color on today’s financing announcement with Lincoln Park Capital (“Lincoln Park”). We are very gratified to have closed this deal with Lincoln Park, in [...]
Full Story »

In Praise of Appeals Court’s Ruling on hESC Funding, What it Means for Regenerative Medicine, and What Is Now Called For

Posted by Gary Rabin on August 27, 2012 for Advanced Cell Technology, Inc
Greetings, You no doubt saw the news on Friday that the “Sherley v. Sebelius” lawsuit opposing federal funding of human embryonic stem cell (hESC) research has been thrown out by a U.S. Appeals court.  We [...]
Full Story »

Reflecting On Our Clinical Trial Results

Posted by Gary Rabin on August 20, 2012 for Advanced Cell Technology, Inc
Greetings, You have no doubt seen today’s announcement about the addition of the University of Edinburgh as a site for our Phase I/II trial for Stargardt’s macular dystrophy (SMD). This follows on the heels of [...]
Full Story »

Summer Momentum: Clinical Trials, Recent Conferences and Reverse Split/Uplisting

Posted by Gary Rabin on July 2, 2012 for Advanced Cell Technology, Inc | comments: 0
First, let me welcome you all to summer. We have been very busy the last few months since our annual shareholders meeting, when we provided a comprehensive update on the company. I realize that many of you are [...]
Full Story »

 
 



The posts and opinions expressed on this site represent those of individual contributors and unless clearly labeled as such do not represent the opinions or policies of Advanced Cell Technology, Inc.

By using this site you acknowledge that Advanced Cell Technology, Inc. is providing the material for informational purposes only and that neither Advanced Cell Technology, Inc. nor their agents, affiliates, partners, or licensors are providing the materials to you for the purposes of giving you medical advice. You should not rely on the materials in deciding on a treatment plan, drug usage, or any other medical advice regarding the materials, and Advanced Cell Technology, Inc., and their licensors strongly urge that you consult with a physician in connection with any and all treatment options that may be available to you.

By using this site, you accept the information, products, and services provided herein "as is". Advanced Cell Technology, Inc. makes no express or implied warranty regarding the accuracy, content, completeness, reliability, operability, or legality of information contained within this site, including, without limitation, the warranties of merchantability, fitness for a particular purpose, and non-infringement of proprietary rights.

In no event shall Advanced Cell Technology, Inc., or its agents, affiliates, partners, or licensors be liable for any direct, special, indirect, incidental or consequential damages or any damages whatsoever resulting from loss related to the use of our sites, whether in an action of contract, breach of warranty, negligence, or other tortious action arising out of or in connection with the use of the materials contained on this site.



(No commercial advertising involvement of any kind has been solicited or accepted in the authorship of the content within a Chairman's company blog.
Advertising placed on this website is not endorsed or affiliated with authors, the chairmen, CEO's, or their respective companies.)